European phase III study demonstrates efficacy by meeting primary endpoint of effect on voluntary motor function; another phase III is ongoing (2/10); drug significantly improves patients' motor function with effects seen on both the voluntary and involuntary motor symptoms associated with the disease (3/10); according to a Danish newsletter, FDA approval "is unlikely based on the existing trial results and the company may have to repeat phase III trials, delaying product launch by several years" (3/10)
Brand Huntexil Generic pridopidine
Company name NeuroSearch Product type Speciality
Therapeutic category CNS Key uses Huntington's Disease
Other Uses N/A Drug Class dopaminergic stabilizer
Dosage From oral Expected Approval 2012+
FDA Filing N/A Last Update date May 25,2010
Link to pipeline report
Link to news article
Link to press releases